Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01952769

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma

A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma

Sponsor: Hadassah Medical Organization

Conditions DIPG

Interventions MDV9300

Updated 6 times since 2017 Last updated: Sep 11, 2016 Started: Feb 28, 2014 Primary completion: Nov 30, 2018 Completion: Apr 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates DIPG and is currently ongoing. Hadassah Medical Organization leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
May 2019 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2018 — May 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hadassah Medical Organization

Data source: Hadassah Medical Organization

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel